Contact Levi & Korsinsky by July 14, 2025 Deadline to Join Class Action Against Iovance Biotherapeutics, Inc. (IOVA)

Core Viewpoint - A class action securities lawsuit has been filed against Iovance Biotherapeutics, Inc. due to alleged securities fraud affecting investors between May 9, 2024, and May 8, 2025 [1][2]. Company Performance and Allegations - The lawsuit claims that Iovance provided overly positive statements while concealing material adverse facts about its growth potential, specifically its inability to generate demand for its treatments [2]. - On July 25, 2024, Iovance announced a reduction in its revenue guidance for the full fiscal year 2024, attributing this to maintenance issues, lower-than-expected Proleukin sales, and the variable pace of treatment initiation at approved centers [2]. - Following the announcement, Iovance's stock price plummeted from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025, marking a decline of approximately 44.8% in one day [2]. Legal Proceedings - Investors who suffered losses during the specified period have until July 14, 2025, to request appointment as lead plaintiff in the lawsuit [3]. - Participation in the lawsuit does not require any out-of-pocket costs for class members [3]. Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as a leading securities litigation firm in the United States [4].